Company / Operating Cash Flow per Share
SAB Biotherapeutics, Inc. Operating Cash Flow per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.69
FY2025
5-year range
-$4.65 / $0.39
FY2021-FY2025
Trend
-35.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-4.65 to $-3.69 over the past 2 years.
Based on SEC 10-K filings.
-3.69 in FY2025.
Improved from $-4.65 to $-3.69 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 35.6% year-over-year.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.69 | -35.6% |
| FY2024 | -$2.72 | +41.5% |
| FY2023 | -$4.65 | -6184.5% |
| FY2022 | $0.08 | -80.1% |
| FY2021 | $0.39 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026